Alzheimer's Disease

$390B+
Total Research Spending
40+
Years of Focused Research
99.6%
Clinical Trial Failure Rate
0
FDA Cures Approved

The Numbers

Alzheimer's disease represents one of the largest research expenditures in modern medicine with the smallest return. Over $390 billion has been committed globally to understanding and treating this disease. In the United States alone, the NIH allocates over $3.2 billion annually to Alzheimer's research.

That spending has produced management strategies. It has not produced a cure. The disease continues to progress exactly as it did 40 years ago. The promises keep changing. The results don't.

First Major Research Initiative 1984
Approvals Since Then 6 drugs
What They Do Slow decline
Cure Status No change

Promises vs. Reality

1984
Promise: Identified amyloid hypothesis. Cure-focused research launched.
1995
Reality: First drug (donepezil) approved. Does not stop disease. Slows cognitive decline temporarily.
2003
Promise: Human genome mapped. Gene therapy next. Cure was 5 years away.
2012
Reality: Major clinical trial failures. Aducanumab halted. Amyloid hypothesis questioned by leading researchers.
2019
Promise: Multiple new monoclonal antibodies in trials. Breakthrough year projected for 2021.
2023
Reality: Lecanemab approved. Slows cognitive decline by 35% over 18 months. Still not a cure. Still not a stop. Still not prevention.
2024
Promise: New compounds in trials. Biomarkers improve. Hope renewed for the fifth time.

Current Research Status

Alzheimer's research stands at an inflection point. The amyloid hypothesis dominated for 40 years. It has not yielded a cure. Recent approvals show slowing of decline, not reversal. The field is broadening: tau pathology, neuroinflammation, vascular dysfunction, lifestyle interventions.

None have produced a cure. All show promise in late-stage trials. This pattern is familiar.

Active Clinical Trials 147+
Phase III Trials 12
Average Trial Success Rate 0.4%
Years to Approval (Average) 13--15

Sources & Methodology

Data compiled from NIH, peer-reviewed sources, and public records.

Primary Sources

  • U.S. National Institutes of Health -- Alzheimer's Research Funding (RePORT Database)
  • FDA Center for Drug Evaluation and Research -- Alzheimer's Approvals Timeline
  • ClinicalTrials.gov -- Alzheimer's Disease Active Trials (147 trials indexed)
  • Fda.gov -- Lecanemab approval documentation (2023)
  • JAMA Neurology -- Aducanumab trial failure analysis (2019--2021)
  • Lancet -- Amyloid Hypothesis Review (Zhang et al., 2016)
  • Alzheimer's Association -- Research Spending Reports (annual)